1. Home
  2. CFND vs ICCC Comparison

CFND vs ICCC Comparison

Compare CFND & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$3.93

Market Cap

27.4M

Sector

N/A

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$6.65

Market Cap

55.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CFND
ICCC
Founded
N/A
1982
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
55.5M
IPO Year
2025
1995

Fundamental Metrics

Financial Performance
Metric
CFND
ICCC
Price
$3.93
$6.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.3K
11.2K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
65.33
EPS
N/A
0.20
Revenue
N/A
$26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$32.70
Revenue Growth
N/A
51.64
52 Week Low
$3.68
$4.32
52 Week High
$9.67
$7.60

Technical Indicators

Market Signals
Indicator
CFND
ICCC
Relative Strength Index (RSI) 45.00 56.18
Support Level $3.75 $5.72
Resistance Level $4.08 $6.87
Average True Range (ATR) 0.17 0.23
MACD 0.04 0.01
Stochastic Oscillator 58.00 87.62

Price Performance

Historical Comparison
CFND
ICCC

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: